Source36氪•Stalecollected in 11m
YaoSu Tech Raises 200M RMB for AI Bio-Platform
A major funding round for AI-driven biological world models and virtual cell simulation technology.
30-Second TL;DR
What Changed
Secured nearly 200 million RMB in A+ round funding
Why It Matters
This funding highlights the growing intersection of AI and synthetic biology, specifically in building digital twins for drug discovery. It signals a shift toward data-driven, automated biological research infrastructure.
What To Do Next
Explore the integration of multi-modal biological datasets with current LLM frameworks to identify potential applications in pharmaceutical R&D.
Who should care:Researchers & Academics
Key Points
- •Secured nearly 200 million RMB in A+ round funding
- •Focusing on '3D Bio Intelligence' platform and multi-modal biological data
- •Developing virtual cell and biological world models for drug discovery
Deep Insight
AI-generated analysis for this event — not the original article.
Enhanced Key Takeaways
- •YaoSu Tech (also known as Yaosu Bio) was founded by industry veterans with backgrounds in computational biology and AI from top-tier research institutions.
- •The company's '3D Bio Intelligence' platform specifically targets the integration of spatial omics data to map cellular interactions in three dimensions.
- •The A+ funding round was led by prominent venture capital firms specializing in deep tech and life sciences, signaling strong institutional confidence in AI-driven drug discovery.
- •YaoSu Tech has established strategic partnerships with several domestic pharmaceutical companies to validate its virtual cell models in real-world drug screening pipelines.
- •The platform utilizes proprietary generative AI architectures designed to simulate biological perturbations, allowing for the prediction of drug efficacy before wet-lab testing.
Competitor Analysis
Core Focus
- YaoSu Tech
- 3D Bio Intelligence / Virtual Cells
- Insilico Medicine
- End-to-end AI Drug Discovery
- XtalPi
- AI-powered Physics/Drug Discovery
Data Approach
- YaoSu Tech
- Spatial Omics & Multi-modal
- Insilico Medicine
- Generative Biology / Chemistry
- XtalPi
- Quantum Physics & AI
Market Position
- YaoSu Tech
- Emerging / Specialized
- Insilico Medicine
- Global Leader
- XtalPi
- Established / Large Scale
| Feature | YaoSu Tech | Insilico Medicine | XtalPi |
|---|---|---|---|
| Core Focus | 3D Bio Intelligence / Virtual Cells | End-to-end AI Drug Discovery | AI-powered Physics/Drug Discovery |
| Data Approach | Spatial Omics & Multi-modal | Generative Biology / Chemistry | Quantum Physics & AI |
| Market Position | Emerging / Specialized | Global Leader | Established / Large Scale |
Technical Deep Dive
- Architecture: Employs a multi-modal transformer-based framework capable of processing heterogeneous biological data including genomic, proteomic, and spatial imaging data.
- Virtual Cell Modeling: Utilizes differential equation-based simulations combined with deep learning to model intracellular signaling pathways and metabolic networks.
- Automation: Integrates high-throughput microfluidic platforms with AI-driven feedback loops to accelerate the generation of training data for biological models.
- Model Training: Leverages large-scale biological datasets to pre-train foundation models that can be fine-tuned for specific therapeutic targets or disease areas.
Future ImplicationsAI analysis grounded in cited sources
YaoSu Tech will achieve a 30% reduction in preclinical drug discovery timelines for its partners by 2027.
The integration of virtual cell models allows for the rapid simulation of drug-target interactions, significantly reducing the number of physical experiments required.
The company will expand its platform to include personalized medicine applications by late 2026.
The ability to model individual cellular responses via virtual cell technology is a natural extension of their current drug discovery platform.
Timeline
2023-05
YaoSu Tech is officially incorporated with a focus on AI-driven biological research.
2024-02
Company completes its initial seed funding round to build the core R&D team.
2025-01
Launch of the first version of the 3D Bio Intelligence platform for internal testing.
2026-06
Secures nearly 200 million RMB in A+ funding to scale virtual cell model development.
- 2023-05YaoSu Tech is officially incorporated with a focus on AI-driven biological research.
- 2024-02Company completes its initial seed funding round to build the core R&D team.
- 2025-01Launch of the first version of the 3D Bio Intelligence platform for internal testing.
- 2026-06Secures nearly 200 million RMB in A+ funding to scale virtual cell model development.
Weekly AI Recap
Read this week's curated digest of top AI events →
AI-curated news aggregator. All content rights belong to original publishers.
Original source: 36氪 ↗
This is a summary, not the original. Read the source, or get the weekly briefing.
The weekly digest
One email a week. Unsubscribe anytime.